
Confirmed Response and Complete Response Rates
Paul L. Swiecicki, MD, of the University of Michigan Rogel Cancer Center, reviews efficacy results from the fully enrolled cohort 1 of the phase 1b/2 OrigAMI-4 study, published in the Journal of Clinical Oncology in 2026.
Episodes in this series

Paul L. Swiecicki, MD, of the University of Michigan Rogel Cancer Center, reviews efficacy results from the fully enrolled cohort 1 of the phase 1b/2 OrigAMI-4 study, published in the Journal of Clinical Oncology in 2026. Among 102 patients with recurrent or metastatic head and neck squamous cell carcinoma evaluable for response, Dr Swiecicki reports a confirmed overall response rate (ORR) of 42% by a blinded independent reviewer, a figure he calls remarkable against historical control. He highlights the depth and durability of response, noting a complete response (CR) rate of 15% and a rate of response lasting 6 months or longer of 24%, though he notes this duration figure is still limited by follow-up time. Dr Swiecicki adds that nearly 31% of patients remained on treatment at the time of the analysis, reflecting an early readout with ongoing follow-up.
Related to this article







